343 related articles for article (PubMed ID: 18784140)
21. Systemic sclerosis - continuing progress in developing clinical measures of response.
Furst D; Khanna D; Matucci-Cerinic M; Clements P; Steen V; Pope J; Merkel P; Foeldvari I; Seibold J; Pittrow D; Polisson R; Strand V
J Rheumatol; 2007 May; 34(5):1194-200. PubMed ID: 17477486
[TBL] [Abstract][Full Text] [Related]
22. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease.
Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Le T; Lee P; Seary ME; Hawker GA; Feldman BM
J Rheumatol; 2012 Feb; 39(2):276-85. PubMed ID: 22247353
[TBL] [Abstract][Full Text] [Related]
23. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.
Rubenfire M; Huffman MD; Krishnan S; Seibold JR; Schiopu E; McLaughlin VV
Chest; 2013 Oct; 144(4):1282-1290. PubMed ID: 23744060
[TBL] [Abstract][Full Text] [Related]
24. Determinants of pulmonary arterial hypertension in scleroderma.
Plastiras SC; Karadimitrakis SP; Kampolis C; Moutsopoulos HM; Tzelepis GE
Semin Arthritis Rheum; 2007 Jun; 36(6):392-6. PubMed ID: 17204309
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary arterial hypertension and HIV infection.
Degano B; Sitbon O; Simonneau G
Semin Respir Crit Care Med; 2009 Aug; 30(4):440-7. PubMed ID: 19634083
[TBL] [Abstract][Full Text] [Related]
26. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future.
Rubin LJ
Rheum Dis Clin North Am; 2008 Feb; 34(1):191-7; viii. PubMed ID: 18329540
[TBL] [Abstract][Full Text] [Related]
27. Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study.
Overbeek MJ; Groepenhoff H; Voskuyl AE; Smit EF; Peeters JW; Vonk-Noordegraaf A; Spreeuwenberg MD; Dijkmans BC; Boonstra A
Respir Res; 2008 Oct; 9(1):68. PubMed ID: 18828919
[TBL] [Abstract][Full Text] [Related]
28. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study.
Vonk MC; Broers B; Heijdra YF; Ton E; Snijder R; van Dijk AP; van Laar JM; Bootsma H; van Hal PT; van den Hoogen FH; van Daele PL
Ann Rheum Dis; 2009 Jun; 68(6):961-5. PubMed ID: 18511546
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive therapies in systemic sclerosis.
Riemekasten G; Sunderkötter C
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii49-51. PubMed ID: 16987836
[TBL] [Abstract][Full Text] [Related]
30. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors.
Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Hawker GA; Feldman BM
J Rheumatol; 2011 Mar; 38(3):462-9. PubMed ID: 21159827
[TBL] [Abstract][Full Text] [Related]
31. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.
Hachulla E; de Groote P; Gressin V; Sibilia J; Diot E; Carpentier P; Mouthon L; Hatron PY; Jego P; Allanore Y; Tiev KP; Agard C; Cosnes A; Cirstea D; Constans J; Farge D; Viallard JF; Harle JR; Patat F; Imbert B; Kahan A; Cabane J; Clerson P; Guillevin L; Humbert M;
Arthritis Rheum; 2009 Jun; 60(6):1831-9. PubMed ID: 19479881
[TBL] [Abstract][Full Text] [Related]
32. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension.
Dimitroulas T; Giannakoulas G; Karvounis H; Gatzoulis MA; Settas L
Semin Arthritis Rheum; 2010 Feb; 39(4):278-84. PubMed ID: 19539354
[TBL] [Abstract][Full Text] [Related]
33. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
Thakkar V; Nikpour M; Stevens WM; Proudman SM
Intern Med J; 2015 Mar; 45(3):248-54. PubMed ID: 25735576
[TBL] [Abstract][Full Text] [Related]
34. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.
Denton CP; Avouac J; Behrens F; Furst DE; Foeldvari I; Humbert M; Huscher D; Kowal-Bielecka O; Matucci-Cerinic M; Nash P; Opitz CF; Pittrow D; Rubin LJ; Seibold JR; Distler O
Arthritis Res Ther; 2011 Jun; 13(3):114. PubMed ID: 21699746
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and management of pulmonary hypertension in systemic sclerosis.
Sweiss NJ; Hushaw L; Thenappan T; Sawaqed R; Machado RF; Patel AR; Gomberg-Maitland M; Husain AN; Archer SL
Curr Rheumatol Rep; 2010 Feb; 12(1):8-18. PubMed ID: 20425528
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
Ramirez A; Varga J
Treat Respir Med; 2004; 3(6):339-52. PubMed ID: 15658881
[TBL] [Abstract][Full Text] [Related]
37. Measuring outcomes in PAH: the gap between the measures that are used and their validity.
Furst DE
Ann N Y Acad Sci; 2007 Jun; 1107():410-6. PubMed ID: 17804569
[TBL] [Abstract][Full Text] [Related]
38. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Sobanski V; Launay D; Hachulla E; Humbert M
Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964
[TBL] [Abstract][Full Text] [Related]
39. ["Pulmonary hypertension" of the gastrointestinal tract in patients with systemic sclerosis: thoughts on a not (yet) existing disease entity].
Müller-Ladner U
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S203-5. PubMed ID: 18814097
[TBL] [Abstract][Full Text] [Related]
40. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult.
Hesselstrand R; Wildt M; Ekmehag B; Wuttge DM; Scheja A
Scand J Rheumatol; 2011 Mar; 40(2):127-32. PubMed ID: 20858146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
